Welkom op de website van MS4 Research Institute
Laatste nieuws
----------
Nieuws
Terug naar overzicht
01-05-2019
Economische evaluatie van Can Do behandeling in een gerandomiseerde gecontroleerde trial
In mei 2019 verscheen van G.A. van Mastrigt, S.M. Evers, M. Heerings, L.H. Visser, R.P. Ruimschotel, A. Hussaarts, L. Duyverman, J. Valkenburg-Vissers, J. Cornelissen, M. Bos, M. van Droffelaar en P.J. Jongen An economic evaluation attached to a single-centre, parallel group, unmasked, randomised controlled trial of a 3-day intensive social cognitive treatment (Can Do treatment) in patients with relapsing remitting multiple sclerosis and low disability in het Journal of Medical Economics.
Hierin communiceerden zij de bevindingen van een economische evaluatie verbonden aan een gerandomiseerde gecontroleerde trial naar de effecten van Can Do behandeling (CDB) bij mensen met relapsing-remitting MS en weinig neurologische beperkingen. CDB is een 3-daagse, intensieve, multidisciplinaire, sociaalcognitieve behandeling. Voor informatie over de resultaten van de RCT met betrekking tot zelfwerkzaamheid zie het volgende item.
In een samenwerking tussen afdeling Health Services Research van de Universiteit Maastricht, MS4 Research Institute en het Nationaal MS Fonds werd onderzocht of CDT (al) na 6 maanden kosteneffectief is ten opzicht van standaard zorg.
Wanneer de EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) werd gebruikt om een Quality-Adjusted Life Year (QALY) te berekenen, was CDT niet kosteneffectief. Echter, wanneer de Multiple Sclerosis Self-Efficay Scale (MSSES) – een maat voor zelfwerkzaamheid (self-efficacy) - of de Short Form 6 Dimensions (SF-6D) als uitkomst werden gebruikt, dan is CDT waarschijnlijk wel kosteneffectief.
Ter informatie volgt hier het abstract: Aims: This trial-based economic evaluation (EE) assesses from a societal perspective the cost-effectiveness of an intensive 3-day cognitive theory-based intervention (CDT), compared to care-as-usual, in patients with relapsing remitting multiple sclerosis (RRMS) and low disability (Expanded Disability Status Scale [EDDS] score < 4.0). Materials and methods: The trial of the EE was registered in the Dutch Trial Register: Trial NL5158 (NTR5298). The incremental cost-effectiveness ratio (ICER) was expressed in cost on the Control sub-scale of the Multiple Sclerosis Self-Efficacy Scale (MSSES) and the incremental cost-utility ratio (ICUR) in the cost per Quality Adjusted Life Years (QALY) using the EQ-5D-5L. Bootstrap, sensitivity, and sub-group analyses were performed to determine the robustness of the findings. Results: The two groups of 79 patients were similar in baseline characteristics. The base case ICER is situated in the northeast quadrant (€72 (40.74/€2,948)) due to a higher MSSES Control score and higher societal costs in the CDT group. The ICUR is situated in the northwest (inferior) quadrant due to losses in QALY and higher societal costs for the CDT group (-0.02/€2,948). Overall, bootstrap, sensitivity, and sub-group analyses confirm the base case findings. However, when the SF-6D is used as a study outcome, there is a high probability that the ICUR is situated in the northeast quadrant. Limitations: The relative short follow-up time (6 months) and the unexpected increase in MSSES Control in the control group. Conclusions: When using the EQ-5D-5L to calculate a QALY, CDT is not a cost-effective alternative in comparison to care as usual. However, when using self-efficacy or SF-6D as outcomes, there is a probability that CDT is cost-effective. Based on the current results, CDT for patients with RRMS clearly show its potential. However, an extended follow-up for the economic evaluation is warranted before a final decision on implementation can be made.
Directe link naar artikel
Terug naar overzicht